Loading...

Summit Therapeutics

DB:UVF1
Snowflake Description

Flawless balance sheet and good value.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
UVF1
DB
£50M
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

Summit Therapeutics plc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of novel medicines to treat rare and infectious diseases in the United Kingdom and North America. The last earnings update was 20 days ago. More info.


Add to Portfolio Compare Print
  • Summit Therapeutics has significant price volatility in the past 3 months.
UVF1 Share Price and Events
7 Day Returns
11.9%
DB:UVF1
0.3%
DE Biotechs
2.3%
DE Market
1 Year Returns
-
DB:UVF1
-7.9%
DE Biotechs
-7.2%
DE Market
UVF1 Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Summit Therapeutics (UVF1) 11.9% 2.6% 41.6% - - -
DE Biotechs 0.3% 3.1% -6.5% -7.9% 43.5% 7.6%
DE Market 2.3% 3.1% 8.8% -7.2% 9.3% 12.3%
1 Year Return vs Industry and Market
  • No trading data on UVF1.
  • No trading data on UVF1.
Price Volatility
UVF1
Industry
5yr Volatility vs Market
Related Companies

Value

 Is Summit Therapeutics undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of Summit Therapeutics to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for Summit Therapeutics.

DB:UVF1 Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 6 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 8.9%
Perpetual Growth Rate 10-Year DE Government Bond Rate 0.2%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for DB:UVF1
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year DE Govt Bond Rate 0.2%
Equity Risk Premium S&P Global 6.7%
Biotechs Unlevered Beta Simply Wall St/ S&P Global 1.46
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 1.456 (1 + (1- 19%) (0%))
1.306
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
1.31
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 0.23% + (1.306 * 6.65%)
8.91%

Discounted Cash Flow Calculation for DB:UVF1 using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for Summit Therapeutics is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

DB:UVF1 DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (GBP, Millions) Source Present Value
Discounted (@ 8.91%)
2019 -26.79 Analyst x2 -24.60
2020 -13.90 Analyst x1 -11.72
2021 -15.40 Analyst x2 -11.92
2022 -28.08 Analyst x2 -19.96
2023 -15.25 Analyst x1 -9.95
2024 9.62 Analyst x1 5.76
2025 13.09 Est @ 36.09% 7.20
2026 16.40 Est @ 25.33% 8.29
2027 19.32 Est @ 17.8% 8.96
2028 21.74 Est @ 12.53% 9.26
Present value of next 10 years cash flows £-38.67
DB:UVF1 DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2028 × (1 + g) ÷ (Discount Rate – g)
= £21.74 × (1 + 0.23%) ÷ (8.91% – 0.23%)
£251.04
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= £251.04 ÷ (1 + 8.91%)10
£106.92
DB:UVF1 Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= £-38.67 + £106.92
£68.25
Equity Value per Share
(GBP)
= Total value / Shares Outstanding
= £68.25 / 160.39
£0.43
DB:UVF1 Discount to Share Price
Calculation Result
Value per share (EUR) From above. €0.43
Current discount Discount to share price of €0.31
= -1 x (€0.31 - €0.43) / €0.43
27.2%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

Current Discount
Amount off the current price Summit Therapeutics is available for.
Intrinsic value
27%
Share price is €0.31 vs Future cash flow value of €0.42554
Current Discount Checks
For Summit Therapeutics to be considered undervalued it must be available for at least 20% below the current price. Less than 40% is even better.
  • Summit Therapeutics's share price is below the future cash flow value, and at a moderate discount (> 20%).
  • Summit Therapeutics's share price is below the future cash flow value, but not at a substantial discount (< 40%).
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Summit Therapeutics's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Summit Therapeutics's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:UVF1 PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-01-31) in GBP £0.09
AIM:SUMM Share Price ** AIM (2019-04-17) in GBP £0.31
Europe Biotechs Industry PE Ratio Median Figure of 30 Publicly-Listed Biotechs Companies 23.37x
Germany Market PE Ratio Median Figure of 422 Publicly-Listed Companies 19.43x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Summit Therapeutics.

DB:UVF1 PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= AIM:SUMM Share Price ÷ EPS (both in GBP)

= 0.31 ÷ 0.09

3.53x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Summit Therapeutics is good value based on earnings compared to the Europe Biotechs industry average.
  • Summit Therapeutics is good value based on earnings compared to the Germany market.
Price based on expected Growth
Does Summit Therapeutics's expected growth come at a high price?
Raw Data
DB:UVF1 PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section 3.53x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 6 Analysts
-19.7%per year
Europe Biotechs Industry PEG Ratio Median Figure of 22 Publicly-Listed Biotechs Companies 1.31x
Germany Market PEG Ratio Median Figure of 272 Publicly-Listed Companies 1.56x

*Line of best fit is calculated by linear regression .

DB:UVF1 PEG (Price to Earnings to Growth) Ratio Calculation
Calculation Outcome
PEG Ratio

= PE Ratio ÷ Net Income Annual Growth Rate

= 3.53x ÷ -19.7%

-0.18x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Summit Therapeutics earnings are not expected to grow next year, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Summit Therapeutics's assets?
Raw Data
DB:UVF1 PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-01-31) in GBP £0.27
AIM:SUMM Share Price * AIM (2019-04-17) in GBP £0.31
Germany Biotechs Industry PB Ratio Median Figure of 15 Publicly-Listed Biotechs Companies 3.89x
Germany Market PB Ratio Median Figure of 570 Publicly-Listed Companies 1.87x
DB:UVF1 PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= AIM:SUMM Share Price ÷ Book Value per Share (both in GBP)

= 0.31 ÷ 0.27

1.17x

* Primary Listing of Summit Therapeutics.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Summit Therapeutics is good value based on assets compared to the DE Biotechs industry average.
X
Value checks
We assess Summit Therapeutics's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Summit Therapeutics has a total score of 4/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Summit Therapeutics expected to perform in the next 1 to 3 years based on estimates from 6 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
-19.7%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Summit Therapeutics expected to grow at an attractive rate?
  • Summit Therapeutics's earnings are expected to decrease over the next 1-3 years, this is below the low risk savings rate of 0.2%.
Growth vs Market Checks
  • Summit Therapeutics's earnings are expected to decrease over the next 1-3 years, this is below the Germany market average.
  • Summit Therapeutics's revenues are expected to decrease over the next 1-3 years, this is below the Germany market average.
Annual Growth Rates Comparison
Raw Data
DB:UVF1 Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:UVF1 Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 6 Analysts -19.7%
DB:UVF1 Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 6 Analysts -17.8%
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 47.6%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 26.1%
Germany Market Earnings Growth Rate Market Cap Weighted Average 11.7%
Germany Market Revenue Growth Rate Market Cap Weighted Average 4.8%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:UVF1 Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (2 months ago) See Below
Future Estimates Average of up to 6 Analyst Estimates (S&P Global) See Below
All numbers in GBP Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:UVF1 Future Estimates Data
Date (Data in GBP Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2024-01-31 43 10 6 3
2023-01-31 15 -15 -29 4
2022-01-31 4 -24 -36 4
2021-01-31 17 -17 -22 5
2020-01-31 15 -21 -21 6
DB:UVF1 Past Financials Data
Date (Data in GBP Millions) Revenue Cash Flow Net Income *
2019-01-31 58 -27 8
2018-10-31 68 -28 14
2018-07-31 68 -34 22
2018-04-30 33 -14 -8
2018-01-31 14 -15 -20
2017-10-31 12 -15 -14
2017-07-31 9 23 -18
2017-04-30 4 11 -21
2017-01-31 2 12 -21
2016-10-31 1 12 -24
2016-07-31 1 -20 -25
2016-04-30 1 -20 -22

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Summit Therapeutics's earnings are expected to decrease over the next 1-3 years, this is not considered high growth.
  • Summit Therapeutics's revenue is expected to decrease over the next 1-3 years, this is not considered high growth.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:UVF1 Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (2 months ago) See Below
Future Estimates Average of up to 6 Analyst Estimates (S&P Global) See Below

All data from Summit Therapeutics Company Filings, last reported 2 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:UVF1 Future Estimates Data
Date (Data in GBP Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2024-01-31 0.01 0.01 0.01 1.00
2023-01-31 -0.15 -0.13 -0.17 2.00
2022-01-31 -0.22 -0.17 -0.25 3.00
2021-01-31 -0.18 -0.12 -0.22 3.00
2020-01-31 -0.16 -0.15 -0.17 2.00
DB:UVF1 Past Financials Data
Date (Data in GBP Millions) EPS *
2019-01-31 0.09
2018-10-31 0.18
2018-07-31 0.29
2018-04-30 -0.12
2018-01-31 -0.31
2017-10-31 -0.22
2017-07-31 -0.28
2017-04-30 -0.34
2017-01-31 -0.35
2016-10-31 -0.38
2016-07-31 -0.40
2016-04-30 -0.36

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Summit Therapeutics will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess Summit Therapeutics's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Summit Therapeutics has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Summit Therapeutics performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Summit Therapeutics's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Summit Therapeutics's year on year earnings growth rate has been positive over the past 5 years.
  • Summit Therapeutics has become profitable in the last year making the earnings growth rate difficult to compare to the 5-year average.
  • Summit Therapeutics has become profitable in the last year making it difficult to compare the Europe Biotechs industry average.
Earnings and Revenue History
Summit Therapeutics's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Summit Therapeutics Company Filings, last reported 2 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:UVF1 Past Revenue, Cash Flow and Net Income Data
Date (Data in GBP Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-01-31 57.62 7.53 11.59 39.17
2018-10-31 68.39 14.46 13.12 39.54
2018-07-31 68.19 21.73 12.05 38.05
2018-04-30 32.82 -8.21 11.83 35.19
2018-01-31 14.17 -20.19 12.00 28.97
2017-10-31 11.51 -13.83 9.93 23.86
2017-07-31 8.78 -17.55 9.86 20.39
2017-04-30 4.05 -20.70 9.28 19.18
2017-01-31 2.38 -21.37 8.28 18.95
2016-10-31 0.87 -23.57 6.64 19.16
2016-07-31 0.52 -24.60 6.04 19.70
2016-04-30 0.93 -22.21 5.13 18.53
2016-01-31 1.28 -20.14 4.77 16.86
2015-10-31 1.60 -16.03 4.69 14.63
2015-07-31 1.84 -12.86 4.02 12.73
2015-04-30 1.92 -12.11 4.62 10.99
2015-01-31 1.89 -11.38 3.70 10.42
2014-10-31 2.07 -10.63 3.76 9.89
2014-07-31 2.48 -9.86 3.59 9.57
2014-04-30 2.23 -7.65 2.42 8.13
2014-01-31 1.84 -6.09 1.94 6.61
2013-10-31 -0.03 -4.81 1.79 5.51
2013-07-31 1.30 -4.13 1.82 3.85
2013-04-30 1.56 -4.18 1.79 3.74
2013-01-31 1.90 -4.23 1.74 4.04
2012-10-31 1.98 -3.86 1.63 3.58
2012-07-31 2.14 -3.49 1.50 3.55
2012-04-30 1.95 -3.09 1.52 3.29

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • Summit Therapeutics has not efficiently used shareholders’ funds last year (Return on Equity less than 20%).
  • Summit Therapeutics used its assets more efficiently than the Europe Biotechs industry average last year based on Return on Assets.
  • Summit Therapeutics has become profitable over the past 3 years. This is considered to be a significant improvement in its use of capital (Return on Capital Employed).
X
Past performance checks
We assess Summit Therapeutics's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Summit Therapeutics has a total score of 3/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Summit Therapeutics's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Summit Therapeutics's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Summit Therapeutics is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Summit Therapeutics's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Summit Therapeutics's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Summit Therapeutics has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Summit Therapeutics Company Filings, last reported 2 months ago.

DB:UVF1 Past Debt and Equity Data
Date (Data in GBP Millions) Total Equity Total Debt Cash & Short Term Investments
2019-01-31 42.54 0.00 26.86
2018-10-31 28.03 0.00 13.04
2018-07-31 33.05 0.00 17.13
2018-04-30 5.77 0.00 27.69
2018-01-31 -3.18 0.00 20.10
2017-10-31 16.10 0.00 31.81
2017-07-31 3.50 0.00 28.29
2017-04-30 -7.98 0.00 19.36
2017-01-31 -3.49 0.00 28.06
2016-10-31 1.09 0.00 34.63
2016-07-31 10.57 0.00 7.00
2016-04-30 16.33 0.00 9.99
2016-01-31 16.08 0.00 16.30
2015-10-31 25.91 0.00 22.19
2015-07-31 30.22 0.00 26.44
2015-04-30 33.87 0.00 29.41
2015-01-31 12.96 0.00 11.27
2014-10-31 17.66 0.00 15.01
2014-07-31 20.00 0.00 17.44
2014-04-30 4.76 0.00 2.03
2014-01-31 4.76 0.00 2.03
2013-10-31
2013-07-31 5.25 0.00 6.00
2013-04-30 5.25 0.00 6.00
2013-01-31 2.85 0.00 3.38
2012-10-31 2.85 0.00 3.38
2012-07-31 4.78 0.00 4.75
2012-04-30 4.78 0.00 4.75
  • Summit Therapeutics has no debt.
  • Summit Therapeutics has not taken on any debt in the past 5 years.
  • Summit Therapeutics has no debt, it does not need to be covered by operating cash flow.
  • Summit Therapeutics has no debt, therefore coverage of interest payments is not a concern.
X
Financial health checks
We assess Summit Therapeutics's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Summit Therapeutics has a total score of 6/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Summit Therapeutics's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Summit Therapeutics dividends. Estimated to be 0% next year.
If you bought €2,000 of Summit Therapeutics shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Summit Therapeutics's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Summit Therapeutics's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:UVF1 Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 6 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 0.9%
Germany Market Average Dividend Yield Market Cap Weighted Average of 325 Stocks 3.1%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.8%
Germany Bottom 25% Dividend Yield 25th Percentile 1.4%
Germany Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:UVF1 Future Dividends Estimate Data
Date (Data in £) Dividend per Share (annual) Avg. No. Analysts
2024-01-31
2023-01-31
2022-01-31 0.00 1.00
2021-01-31 0.00 1.00
2020-01-31 0.00 1.00

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Summit Therapeutics has not reported any payouts.
  • Unable to verify if Summit Therapeutics's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Summit Therapeutics's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Summit Therapeutics has not reported any payouts.
Future Payout to shareholders
  • No need to calculate the sustainability of Summit Therapeutics's dividends in 3 years as they are not expected to pay a notable one for Germany.
X
Income/ dividend checks
We assess Summit Therapeutics's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Summit Therapeutics afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Summit Therapeutics has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Summit Therapeutics's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Glyn Edwards
COMPENSATION £628,629
AGE 62
TENURE AS CEO 7 years
CEO Bio

Mr. Glyn O. Edwards, MBE has been the Chief Executive Officer of Summit Therapeutics plc since April 4, 2012. Mr. Edwards has a wealth of expertise garnered from a thirty-year career in the life sciences industry, during which time he has held a number of senior executive and business development roles. He served as the Chief Executive Officer of Antisoma plc since March 1998. Prior to joining Antisoma, Mr. Edwards served as the Vice President of Business Development at Therapeutic Antibodies Inc. since January, 1998. He has worked with Celltech PLC and 3M United Kingdom PLC. Mr. Edwards was the Founder of Oros Instruments Limited. From 1995 to 1998, he served as a Consultant of TAb through Elara Associates Limited. Mr. Edwards served as the Chairman of Executive Board and Member of Executive Board at Antisoma Research Limited. He serves as an Executive Director at Xanthus Pharmaceuticals, Inc. He has been an Executive Director of Summit Therapeutics plc since April 4, 2012. He serves as a Director of Elara Associates Limited, Cancer Therapeutics Limited. He served as an Executive Director of Antisoma plc from March 16, 1998 to February 28, 2011. Mr. Edwards is a Member of Review Panel of Heptagon Fund. He holds a BS degree in Biochemistry from Bristol University and an MS degree in Economics from London Business School.

CEO Compensation
  • Glyn's compensation has been consistent with company performance over the past year.
  • Glyn's remuneration is higher than average for companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the Summit Therapeutics management team in years:

2.8
Average Tenure
52
Average Age
  • The tenure for the Summit Therapeutics management team is about average.
Management Team

Glyn Edwards

TITLE
CEO & Executive Director
COMPENSATION
£629K
AGE
62
TENURE
7 yrs

David Roblin

TITLE
COO, Chief Medical Officer and President of Research & Development
COMPENSATION
£451K
AGE
52
TENURE
2 yrs

Kay Davies

TITLE
Co-Founder
AGE
68

Melissa Strange

TITLE
VP of Finance & Company Secretary
AGE
38
TENURE
0.3 yrs

Michelle Avery

TITLE
Director of Investor Relations
TENURE
3.6 yrs

Richard Pye

TITLE
Senior Director of Corporate Affairs & Communications

Jonathon Tinsley

TITLE
Chief Scientific Officer of DMD
AGE
59
TENURE
5.5 yrs

Richard Vickers

TITLE
Senior Vice President of Anti-Infectives
AGE
42
TENURE
5.5 yrs

Anne Heatherington

TITLE
Head of Clinical Development and Quantitative Sciences
TENURE
1.9 yrs

Dave Powell

TITLE
Senior Vice President of Research
AGE
49
TENURE
1.9 yrs
Board of Directors Tenure

Average tenure and age of the Summit Therapeutics board of directors in years:

5.2
Average Tenure
61
Average Age
  • The tenure for the Summit Therapeutics board of directors is about average.
Board of Directors

Frank Armstrong

TITLE
Non-Executive Chairman
COMPENSATION
£223K
AGE
61
TENURE
5.8 yrs

Glyn Edwards

TITLE
CEO & Executive Director
COMPENSATION
£629K
AGE
62
TENURE
7 yrs

Kay Davies

TITLE
Co-Founder
AGE
68

Valerie Andrews

TITLE
Independent Non-Executive Director
COMPENSATION
£128K
AGE
58
TENURE
4.6 yrs

Dave Wurzer

TITLE
Independent Non-Executive Director
COMPENSATION
£121K
AGE
60
TENURE
4.2 yrs

Marcel van den Heuvel

TITLE
Member of Scientific Advisory Board

Francesco Muntoni

TITLE
Member of Scientific Advisory Board

Roger Patient

TITLE
Member of Scientific Advisory Board

Edith Sim

TITLE
Member of Scientific Advisory board

Bob Sim

TITLE
Member of Scientific Advisory board
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
17. Jul 18 Buy Frank Armstrong Individual 16. Jul 18 16. Jul 18 25,000 €0.45 €11,160
16. Jul 18 Buy Glyn Edwards Individual 13. Jul 18 13. Jul 18 150,000 €0.43 €64,565
X
Management checks
We assess Summit Therapeutics's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Summit Therapeutics has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Company Info

Description

Summit Therapeutics plc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of novel medicines to treat rare and infectious diseases in the United Kingdom and North America. It is conducting clinical programmes focused on the genetic disease Duchenne muscular dystrophy (DMD) and the infectious disease Clostridium difficile infection (CDI). The company’s lead DMD product candidate is ezutromid, an orally administered small molecule, which is in Phase II clinical trial; and lead CDI product candidate is ridinilazole, an orally administered small molecule antibiotic that has completed Phase II clinical trials. It has strategic alliance with the University of Oxford to develop utrophin modulators. The company was formerly known as Summit Corporation plc and changed its name to Summit Therapeutics plc in February 2015. Summit Therapeutics plc was founded in 2003 and is based in Abingdon, the United Kingdom.

Details
Name: Summit Therapeutics plc
UVF1
Exchange: DB
Founded: 2003
£57,386,190
160,389,881
Website: http://www.summitplc.com
Address: Summit Therapeutics plc
136a Eastern Avenue,
Milton Park,
Abingdon,
Oxfordshire, OX14 4SB,
United Kingdom
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
AIM SUMM Ordinary Shares London Stock Exchange AIM Market GB GBP 14. Oct 2004
OTCPK SMXX.F Ordinary Shares Pink Sheets LLC US USD 14. Oct 2004
DB UVF1 Ordinary Shares Deutsche Boerse AG DE EUR 14. Oct 2004
NasdaqGM SMMT SPONS ADS Nasdaq Global Market US USD 06. Mar 2015
Number of employees
Current staff
Staff numbers
61
Summit Therapeutics employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/04/18 00:31
End of day share price update: 2019/04/17 00:00
Last estimates confirmation: 2019/04/02
Last earnings filing: 2019/03/29
Last earnings reported: 2019/01/31
Last annual earnings reported: 2019/01/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.